Ranbaxy Will Produce Internal Audits To U.S. DOJ But Warns Of Impact To Industry From "Bad Policy"
This article was originally published in PharmAsia News
Executive Summary
Ranbaxy says it has fully cooperated with the U.S. Department of Justice investigation into company practices and will produce documents requested in a subpoena motion filed in a Maryland U.S. District Court, the company said in a response filed July 15